Episode
#202 Dementia Part 2: Gray Matters Segment
- Published
- Mar 12, 2026
- Duration seconds
- 2836
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/core-im-internal-medicine-podcast-60389/episodes/202-dementia-part-2-gray-matters-segment/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389/202-dementia-part-2-gray-matters-segment.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Most clinicians see dementia medications on the med rec, but many of us aren’t sure how much they actually help . In this episode we break down donepezil, memantine, and the new anti-amyloid drugs, and when to stop them. • Do cholinesterase inhibitors really work? • What should clinicians know about lecanemab and donanemab before referring patients? • How much benefit should we expect and for how long? • When should you deprescribe dementia medications ? 🔹 Sponsor: Caraway’s cookware set is a favorite for a reason. For 10% off, go to Carawayhome.com/ CoreIM or use code CoreIM at checkout. 🔹 Transcript and Shownotes 02:27 | Deep Dive 1: How do we deliver the news of a diagnosis of dementia? 09:41 | Deep Dive 2: Prescribing medications for cognitive decline 29:30 | Deep Dive 3: Patient-centered management for a patient with cognitive decline 35:46 | Deep Dive 4: Planning for an uncertain future Tags: CoreIM, Internal Medicine, Medical Education, Cognitive Screening, primary care, nurse practitioner, physician assistant Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy